Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cellectis SA (CLLS)
NASDAQ:CLLS
Holding CLLS?
Track your performance easily
CLLS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.53 - $3.55
Previous Close$1.64
Volume87.89K
Average Volume (3M)61.61K
Market Cap
$112.64M
Enterprise Value$27.38M
Total Cash (Recent Filing)$136.71M
Total Debt (Recent Filing)$51.45M
Price to Earnings (P/E)―
Beta4.71
Next Earnings
May 07, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.03
Shares Outstanding100,090,000
10 Day Avg. Volume61,613
30 Day Avg. Volume61,607
Standard Deviation0.34
R-Squared0.23
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)1.93
Price to Sales (P/S)210.79
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue17.50
Enterprise Value/Gross Profit1.52K
Enterprise Value/Ebitda-0.44
Forecast
1Y Price Target
$8.00Price Target Upside387.80% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Cellectis SA News
PremiumCompany Announcements
Cellectis S.A. Reports Q3 2024 Financial Results and Updates
PremiumCompany Announcements
Cellectis SA Advances CAR T-cell Therapy for Solid Tumors
PremiumCompany Announcements
Cellectis S.A. Releases Interim Financial ResultsPremiumCompany Announcements
Cellectis SA to Unveil Q3 2024 Financial ResultsBulls Say, Bears Say
Bulls Say
Financial PerformanceCellectis reported a quarter-end cash balance of $264M, up from $165M at YE2023.
Partnership ProgressThe AstraZeneca research partnership is off to a strong start with three programs underway and meaningful revenues triggered to date.
Revenue And Financial OutlookCLLS reported 3Q24 revenue of $18.1M vs. our estimate of $11.2M.
Bears Say
Pipeline PrioritizationUCART123 (AMELI-01 trial) is deprioritized.
Product DevelopmentThe development of UCART123 in acute myeloid leukemia (AML) was deprioritized.
Strategic FocusCellectis management has decided to focus their resources on the UCART22 and UCART20x22 programs, and are deprioritizing the development of UCART123 in AML.
---
Ownership Overview
―
Insiders
3.47% Mutual Funds
10.55% Other Institutional Investors
85.98% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
CLLS FAQ
What was Cellectis SA’s price range in the past 12 months?
Cellectis SA lowest stock price was $1.53 and its highest was $3.55 in the past 12 months.
What is Cellectis SA’s market cap?
Currently, no data Available
When is Cellectis SA’s upcoming earnings report date?
Cellectis SA’s upcoming earnings report date is May 07, 2025 which is in 137 days.
How were Cellectis SA’s earnings last quarter?
Cellectis SA released its earnings results on Nov 04, 2024. The company reported -$0.23 earnings per share for the quarter, missing the consensus estimate of -$0.203 by -$0.027.
Is Cellectis SA overvalued?
According to Wall Street analysts Cellectis SA’s price is currently Undervalued.
Does Cellectis SA pay dividends?
Cellectis SA does not currently pay dividends.
What is Cellectis SA’s EPS estimate?
Cellectis SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cellectis SA have?
Cellectis SA has 72,093,636 shares outstanding.
What happened to Cellectis SA’s price movement after its last earnings report?
Cellectis SA reported an EPS of -$0.23 in its last earnings report, missing expectations of -$0.203. Following the earnings report the stock price went up 1.136%.
Which hedge fund is a major shareholder of Cellectis SA?
Among the largest hedge funds holding Cellectis SA’s share is Bpifrance SA. It holds Cellectis SA’s shares valued at N/A.
---
Cellectis SA Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.00 (387.80% Upside)
$8.00 (387.80% Upside)
Hedge Fund Trend
Decreased
By 2.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 1.1%
Last 30 Days ▼ 3.9%
Last 30 Days ▼ 3.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-53.80%
12-Months-Change
Fundamentals
Return on Equity
-101.50%
Trailing 12-Months
Asset Growth
88.78%
Trailing 12-Months
Company Description
Cellectis SA
Cellectis SA is a biopharmaceutical company, which engages in the research and development of genome engineering technology. The company operates through the following business segments: Therapeutics and Plants. The Therapeutics segment is focused on the development of products in the field of immune-oncology and of novel products outside immuno-oncology to treat other human diseases. The Plants segment focuses on applying its gene-editing technologies to develop new generation plant products in the field of agricultural biotechnology through its own efforts or through alliances with other companies in the agricultural market. Its therapeutic products are still in the preclinical stage which is developed for various kinds of tumors. Cellectis was founded by David J. Sourdive and André Choulika on February 20, 1999 and is headquartered in Paris, France.
---
CLLS Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant strategic and financial progress, particularly with the AstraZeneca collaboration and improved cash position. However, challenges such as the de-prioritization of UCART123 and delays in data release were noted. Overall, the sentiment is balanced with a positive outlook on future developments.Read More>---
CLLS Stock 12 Month Forecast
Average Price Target
$8.00
▲(387.80% Upside)
Technical Analysis
Best Analysts Covering CLLS
1 Year
1 Year Success Rate
9/26 ratings generated profit
1 Year Average Return
-22.72%
reiterated a buy rating 6 months ago
Copying Hartaj Singh's trades and holding each position for 1 Year would result in 34.62% of your transactions generating a profit, with an average return of -22.72% per trade.
---